Monthly Communication Report

Registrant name:	Ross Wallace
Client:	Canadian Biosimilars Forum/Forum canadien des biosimilaires
Associated registration:	929211-358995-3
Communication date:	2018-05-22
Posted date:	2018-06-15

Designated Public Office Holders who participated in the communication:	Kelly Robinson, Director Health Products and Therapeutics Branch, Health Canada (HC) Jemma Fraije, A/ Regulatory Affairs Supervisor Health Products and Therapeutics Branch, Health Canada (HC) Anthony Ridgway, Senior Regulatory Scientist Health Products and Therapeutics Branch, Health Canada (HC) Stephanie Hardy, Manager, Policy Unit Health Products and Therapeutics Branch, Health Canada (HC) Karen Reynolds, Executive Director Strategic Policy Branch, Health Canada (HC) Johanne Veenstra, Senior Regulatory Officer Health Products and Therapeutics Branch, Health Canada (HC) Jian Wang, Division Chief Health Products and Therapeutics Branch, Health Canada (HC) Liz Anne Gillham-Eisen, A Director Health Products and Therapeutics Branch, Health Canada (HC) Emily Griffiths, Subject Matter / Technical Specialist Health Products and Therapeutics Branch, Health Canada (HC) Megan Bettle, Director Health Products and Therapeutics Branch, Health Canada (HC) Lindsay Elmgren, Director, Centre for Biologics Evaluation Health Products and Therapeutics Branch, Health Canada (HC) Evelyn Soo, Associate to the Director General Health Products and Therapeutics Branch, Health Canada (HC) Cathy Parker, Director General Health Products and Therapeutics Branch, Health Canada (HC) Agnes Klein, Senior Medical Advisor Health Products and Therapeutics Branch, Health Canada (HC) Michele Chadwick, Manager Health Products and Therapeutics Branch, Health Canada (HC) Georgette Roy, Director, Office of Regulatory Affairs Health Products and Therapeutics Branch, Health Canada (HC)
Subject Matter of the communication:	Health